Mit dem Laden der Karte akzeptieren Sie die Datenschutzerklärung von OpenStreetMap Foundation.
Mehr erfahren

Karte laden

Companies

No filter results

Unfortunately, nothing matched your filter. Please try again with different criteria.

Das Team von Ordinary Seafood bei einer Verkostung ihrer Produkte. Von links: Fabian Machens, Tim Meier, Anton Pluschke © Anton Pluschke

3 questions with Ordinary Seafood: »In the market for fish and seafood alternatives, we’re breaking completely new ground«

The way we hunt our seafood and farm our fish is harmful to animals, their natural habitats and our health. Ordinary Seafood has set out to develop vegan alternatives, that feel and taste exactly like the original. In our interview, founder and CEO Dr. Anton Pluschke and Head of R&D Dr. Fabian Machens share their start-up story, why Potsdam Science Park is the perfect location them – and the peculiarities of creating the perfect fake shrimp.

Julia Eschenbrenner & Jonas Massmann poroUS GmbH © Sujeetha Lalitha

3 questions with POROUS: “The opportunity to contribute to the health of many people around the world is our driver. It is also what convinced the jury”

For its work in early osteoporosis detection, poroUS GmbH, based in Potsdam Science Park, is receiving funding of €2.5 million through the European Innovation Council Accelerator Grant. In our interview, CEO Julia Eschenbrenner and CTO Jonas Massmann explain how they managed to stand out during the application process and what opportunities the funding will provide them in the coming years.

Andrey Poloznikov Mimi-Q

3 Questions with Mimi-Q: »We Can Develop Drugs More Quickly and Effectively at a Lower Cost – without Using Animal Testing«

Animal testing continues to play a key role in the approval of new drugs. The startup Mimi-Q has developed a testing process that closes the gap between basic research and clinical studies. In future, it may also start to replace these tests and thus greatly reduce their use. In this interview, founder Dr. Andrey Poloznikov tells us about the idea behind Mimi-Q, how the company’s process could speed up drug development and how it benefits from Potsdam Science Park.

PSP Conference

PSP Conference 2022 – Prospects and New Innovations in Biotechnology and Bioeconomy

Biotechnology is a key technology which can be used to feed the growing world population, save resources and improve the health of many millions of people. Bioeconomy entails the transition to a fossil-free economy. On 20 October 2022, renowned scientists and innovation drivers from business and startups gathered at this year’s PSP Conference at the Potsdam Science Park with the motto ”Biotechnology & bioeconomy – the obstacle course of the future” to discuss bioeconomy’s potential and success stories.

Das Team der kez.biosolutions GmbH im Potsdam Science Park (v.l.n.r.): Dr. Mirko Joppe, Dr. Alexander Rittner, Jan Degen

3 Questions with kez.biosolutions: »A Revolution in Basic Research« – Optimised Antibiotics Based on Natural Ingredients to Combat Resistant Pathogens

Antibiotic-resistant pathogens are becoming a serious concern. In 2019, more people died from infections with resistant pathogens than of HIV and malaria together. kez.biosolutions GmbH is a start-up that is working on a ground-breaking process for developing brand-new, optimised substances from natural ingredients, such as sugar beets, with substrates in a bioreactor. In our interview, kez.biosolutions founder Dr. Alexander Rittner tells us about the unique platform technology developed in a decade of basic research and about the young company’s plans for its future at Potsdam Science Park.

3 Questions with DiGOS: “Making the World a Little Bit Safer” – Fighting Space Debris with Laser Pulses

7,000 – 28,000 km/h. That’s the kind of incredible speeds satellites can travel at in space. They orbit the earth at distances of 100-23,000 km. Inch-perfect tracking of their positions is a gruelling challenge. One of the few companies in the world that are up to the task is DiGOS in Potsdam. In fact they’re so good at it they’re planning to put up their own building in the new Technology Campus at the Potsdam Science Park. Managing Director André Kloth tells us all about how they manage to track satellites down to the millimeter via Satellite Laser Ranging (SLR) and how they plan to help reduce space debris (space junk).

Rooftop Pitch Potsdam: four minutes to win over investors

16 May 2022 marked the third instalment of Rooftop Pitch Potsdam. Around a dozen startup teams joined the event at the WIS building to present their business ideas to a selection of investors. There was a lot at stake: the latter were ready to fund good ideas and teams to the tune of up to €300,000 and wield their rolodexes on their behalf.

3 Questions with Vragments: “We often come in where corporate IT departments are hitting their limits”

Virtual Reality has been a buzzword for some time now. Vragments is one company that’s helping companies digitalize using innovative solutions such as VR. From their beginnings in immersive storytelling and projects like a virtual model of Berlin’s new BER airport, they’re now shifting towards advising clients on their Industry 4.0 transformation processes. CEO Professor Linda Rath tells us about their goals, the approach they’ve been taking, and why the Potsdam Science Park is the best place to be for what they’re doing.

potsdam_sciencepark_ripac-labor_heiko_ruediger©standortmanagement_golm_gmbh-julia_hinz.jpg

3 questions to Molzym: “Our goal is to minimise the time needed for DNA analysis in sepsis diagnostics from 24 down to four hours”

Molecular diagnostics are dedicated to analysing genetic material. Just as DNA is highly complex in itself and must be isolated from other molecules, the methods and procedures in this field are highly complicated. Bremen-based company Molzym offers molecular diagnostics solutions for a wide range of pathogens that cause infectious diseases. At Potsdam Science Park, the company is conducting research to considerably speed up molecular diagnostics in the area of sepsis, also known as blood poisoning, to allow for improved targeted treatment.

RIPAC-LABOR – a successful business preparing for a new phase

One of the biggest business success stories at the Potsdam Science Park has been RIPAC-LABOR. After more than 18 years at the helm, successful founder and entrepreneur Dagmar Köhler-Repp has passed the mantle to Heiko Rüdiger, a veteran executive who has plans to give the company a stronger international presence, especially now that it’s part of Dopharma.

Johannes Zier leitet den Start-up Service der Universität Potsdam bei Potsdam Transfer

“The most important thing is: talk about your ideas, don’t keep quiet” – a conversation with Johannes Zier, International Start-up Service at the University of Potsdam.

With over 25 years of experience supporting startups, 300 of them nurtured over the last 10 years alone, and ranked 3rd in Startup Radar 2021, Potsdam Transfer’s Start-up Service is one of Germany’s most successful. In this interview we hear from its head of, Johannes Zier, on how he and the team got to this position, the advice he gives to scientists looking to found start-ups, and why the Potsdam Science Park is so important for the start-up scene in Germany and beyond.

Das Unternehmen Biotx.ai mit Sitz im Potsdam Science Park schafft es mit seiner KI-Plattform, komplexe Muster in genomischen Daten zu erkennen, und kann so präzise Vorhersagen zur Wirksamkeit von neuen Therapien treffen.

3 Questions to Biotx.ai: “With our AI platform, we have achieved something in three months that previously took the industry several years to do”

Artificial intelligence is one of the big trending topics of our time. But what exactly can it do? Biotx.ai, a company based in the Potsdam Science Park, manages to recognize complex patterns in genomic data with its AI platform, enabling it to make precise predictions about the efficacy of new therapies. Their approach could radically shorten the time needed for such studies, revolutionizing an entire industry. Biotx.ai COO Christian Hebenstreit explains how this works in our interview.

potsdam_sciencepark-geschaeftsfuehrung-gruender-BIOCYC © Standortmanagement Golm GmbH/Karen Esser

3 questions to biocyc – “With our new antibody production process, we are one of the few companies in the world that are able to do this”

In a way, biocyc is one of the hidden champions of the Potsdam Science Park. Producing peptides for both the pharmaceutical industry and research as well as antibodies for cancer diagnostics, their success allows them to build their own production building in the Potsdam Science Park. In our interview, biocyc CEO Alexander Gorczyza talks about antibodies for cancer diagnostics and why the Potsdam Science Park is the ideal location for the growing company.

3 Questions to QMEDIS – “We are working on the 2D printing of drugs”

Starting in January 2022, new companies and research groups will move into the newly built H-LAB in the Potsdam Science Park. Among them will be QMEDIS Analytics, a contract lab where drugs are not only analysed but also produced. In our interview, Dr. Dennis Stracke explains how the lab works and how drug printers could revolutionise the industry.

3 Questions to GILUPI – “We think our way of diagnosing cancer cells is ground-breaking”.

Scientists around the world are researching ways for a better treatment of cancer. One of them is offered by GILUPI, a company founded in 2006. With their product, medical personnel can extract cancer cells from the blood. Dr. Christian Jurinke has been the company’s CEO since 2018. In our interview, he explains why good diagnostics are crucial for cancer therapy and why they have moved into their new office at GO:IN 2 in the Potsdam Science Park.

“We need world-class talent” – Interview with Dr Sven Sewitz, Head of Biodata Innovation at Eagle Genomics

Research and business in the field of biology face the immense challenge of analysing and evaluating huge amounts of data. The company Eagle Genomics has set out to make this complexity manageable with the help of network science and artificial intelligence. In 2021, the company will open its first German location in the Potsdam Science Park. A conversation with Dr Sven Sewitz, Head of Biodata Innovation at Eagle Genomics.

Nicolas Hartmann and vly: the reinvention of milk

Nicolas Hartmann and the vly team offer a milk derived from pea proteins. Thanks to a TV program, they became known throughout Germany. What few people know: In order to build up their start-up, they received valuable support from Potsdam Transfer at the University of Potsdam: their EXIST-Gründerstipendium. The story of a start-up with the ambition to make the world a better place.

An entrepreneur and her story

With RIPAC-LABOR GmbH, Dagmar Köhler-Repp has written start-up history in the capital region. Now her company is set to grow further in the Potsdam Science Park. We get closer to perhaps the most exciting founder personality in Brandenburg.